ArticleMayo Clinic proceedings. Innovations, quality & outcomes2026
Glycemic Markers and Cardiometabolic Multiple Long-Term Conditions: Comparative Roles of Glycated Hemoglobin and Fasting Plasma Glucose in the English Longitudinal Study of Ageing.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To examine and contrast the associations of glycated hemoglobin (HbA1c) and fasting plasma glucose (FPG) with the risk of cardiometabolic multiple long-term conditions (cMLTC) and evaluate their incremental predictive utility. Patients and Methods: The study analyzed 2233 adults (mean age 63; 1009 (45.2%) men) free of hypertension, coronary disease, diabetes, and stroke at baseline (wave 4; 2008-2009). Incident cardiometabolic multimorbidity (≥2 of these conditions) was assessed at wave 10 (2021-2023). Logistic regression, restricted cubic splines, and discrimination metrics evaluated predictors and predictive performance. Results: Over 12-15 years, 129 participants developed cMLTC (57.8 per 1000; 95% CI, 48.5-68.3). Restricted cubic splines showed continuous, dose-response relationships between HbA1c and FPG with cMLTC risk. HbA1c was strongly associated with cMLTC (per 1% increase, OR 1.99; 95% CI, 1.51-2.63; highest vs lowest tertile, OR 3.15; 95% CI, 2.00-4.94), whereas FPG associations were more modest (per 1 mmol/L: OR 1.39; 95% CI, 1.18-1.64; tertile: OR 1.98; 95% CI, 1.23-3.19) and attenuated after mutual adjustment. Adding HbA1c to established risk factors improved discrimination (ΔC-index=0.0344, Conclusion: In this nationally representative cohort of older adults in England, higher HbA1c and FPG levels were each associated with an increased risk of cMLTC and enhanced risk prediction. However, HbA1c emerged as a substantially stronger and more informative marker than FPG.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.